
Opinion|Videos|November 26, 2025
Treatment Primer on TNBC
Fact checked by: Nicole Canfora Lupo
This segment summarizes the challenges of metastatic TNBC and highlights how current treatment decisions rely on biomarkers and evolving molecular profiling to guide a personalized therapeutic approach.
Advertisement
Episodes in this series

Now Playing
Metastatic triple-negative breast cancer (mTNBC) presents a significant therapeutic challenge due to its aggressive nature and lack of hormone or HER2 targets. The current treatment algorithm emphasizes a personalized approach based on biomarker status, prior therapies, and patient health or clinical trial enrollment when available. Overall, treatment decisions are increasingly guided by molecular profiling and emerging biomarkers to optimize outcomes and balance efficacy with tolerability.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
2
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
3
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
4
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
5


































































































